Market: NASD |
Currency: USD
Address: 14 Einstein Street
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
📈 Enlivex Therapeutics Ltd. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$13.00
-
Upside/Downside from Analyst Target:
1,138.10%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
50-100%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2019 |
- |
$0.125000 |
- |
2019-03-06 |
- |
Stock split |
|
Total Amount for 2019: $0.125000 |
| 2017 |
- |
$0.200000 |
- |
2017-09-25 |
- |
Stock split |
|
Total Amount for 2017: $0.200000 |
📅 Earnings & EPS History for Enlivex Therapeutics Ltd.
| Date | Reported EPS |
|---|
| 2025-05-30 | -0.15 |
| 2025-03-31 | -0.23 |
| 2024-11-29 | -0.12 |
| 2024-08-30 | -0.16 |
| 2024-06-14 | -0.22 |
| 2024-03-29 | -0.48 |
| 2023-11-09 | -0.32 |
| 2023-09-01 | -0.37 |
| 2023-06-16 | -0.39 |
| 2023-03-31 | -0.39 |
| 2022-12-02 | -0.31 |
| 2022-08-22 | -0.54 |
| 2022-05-27 | -0.45 |
| 2022-04-29 | -0.26 |
| 2021-11-19 | -0.19 |
| 2021-08-06 | -0.17 |
| 2021-05-28 | -0.19 |
| 2021-04-30 | -0.43 |
| 2020-10-30 | -0.16 |
| 2020-08-14 | -0.23 |
| 2020-05-18 | -0.07 |
| 2020-04-30 | -0.28 |
📰 Related News & Research
No related articles found for "enlivex therapeutics".
